v3.25.2
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2024
Income Taxes [Abstract]  
Schedule of Deferred Tax Assets and Liabilities The tax effects of temporary differences that gave rise to significant portions of the deferred tax assets and liabilities were as follows:
   December 31, 
   2024   2023 
Deferred tax assets:        
Capitalized research and development expenditures  $5,492,204   $3,253,225 
Net operating loss carryforwards   3,361,350    2,183,803 
Research and development tax credits   1,254,707    1,253,836 
Capitalized license fees   781,373    
—
 
Share-based compensation   46,122    24,969 
Accruals and other   200,285    13,548 
Deferred tax assets   11,136,041    6,729,381 
           
Less valuation allowance   (11,136,041)   (6,729,381)
Net deferred tax assets  $
—
   $
—
 
Schedule of Reconciliation of Federal Income Tax Rate

A reconciliation of the federal income tax rate to the Company’s effective tax rate is as follows:

 

   December 31, 
   2024   2023 
Federal tax benefit at statutory rate   21.0%   21.0%
State tax, net of federal benefit   6.9    6.9 
Research and development credits   1.1    6.4 
Provision true-up   (0.1)   
—
 
Permanent differences   (3.1)   
—
 
Change in valuation allowance   (25.8)   (34.3)
Effective income tax rate   
—
%   
—
%